EAU, AUA and NICE Guidelines on Surgical and Minimally Invasive Treatment of Benign Prostate Hyperplasia: A Critical Appraisal of the Guidelines Using the AGREE-II Tool

Dmitry Enikeev^a Vincent Misrai^b Enrique Rijo^c Roman Sukhanov^a
Denis Chinenov^a Magomed Gazimiev^a Mark Taratkin^a Camilla Azilgareeva^d
Andrey Morozov^a Thomas R.W. Herrmann^{e, f} Petr Glybochko^a

^aInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; ^bDepartment of Urology, Clinique Pasteur, Toulouse, France; ^cDepartment of Urology, Hospital Quirón Salud, Barcelona, Spain; ^dInternational School "Medicine of the Future", Sechenov University, Moscow, Russia; ^eDepartment of Urology, Spital Thurgau AG, Frauenfeld, Switzerland; ^fDepartment of Urology, Hanover Medical School (MHH), Hanover, Germany

Keywords

Appraisal of Guidelines for Research and Evaluation · Benign prostate hyperplasia · Minimally invasive treatment · Guidelines

Abstract

Objective: To critically appraise the methodological rigour of the clinical practice guidelines (CPGs) vis-à-vis BPH surgery as used by specialist research associations in the US, Europe and UK, and to compare whether the guidelines cover all or only some of the available treatments. **Methods:** The current guidelines issued by the EAU, AUA and NICE associations have been analyzed by 4 appraisers using the AGREE-II instrument. We also compared the recommendations given in the guidelines for surgical and minimally invasive treatment to find out which of these CPGs include most of the available treatment options. **Results:** According to the AGREE II tool, the median scores of domains were: domain 1

scope and purpose 66.7%, domain 2 stakeholder involvement 50.0%, domain 3 rigor of development 65.1%, domain 4 clarity of presentation 80.6%, domain 5 applicability 33.3%, domain 6 editorial independence 72.9%. The overall assessment according to AGREE II is 83.3%. The NICE guideline scored highest on 5 out of 6 domains and the highest overall assessment score (91.6%). The EAU guideline scored lowest on 4 out of 6 domains and has the lowest overall assessment score (79.1%). **Conclusions:** The analyzed CPGs comprehensively highlight the minimally invasive and surgical treatment options for BPH. According to the AGREE II tool, the domains for clarity of presentation and editorial independence received the highest scores. The stakeholder involvement and applicability domains were ranked as the lowest. Improving the CPG in these domains may help to improve the clinical utility and applicability of CPGs.

© 2021 The Author(s)
Published by S. Karger AG, Basel

Introduction

Benign Prostatic Obstruction (BPO) due to Benign Prostatic Hyperplasia (BPH) is one of the most common urological diseases and often requires surgical treatment [1–3]. A number of less invasive procedures have come to light recently allowing us to pursue a more personalized approach. In this regard, various randomized controlled studies (RCTs), systematic reviews and meta-analyses have been conducted. Evidence-based data supporting the effectiveness of these procedures led to them being reflected in the recently updated (up to July 2020) clinical practice guidelines (CPGs).

There are a number of tools that can be used to assess the quality of the guidelines. One of the most validated and extensively used is the AGREE (Appraisal of Guidelines for Research and Evaluation) instrument. It was developed to address the issue of variability in the quality of the guidelines and in the development process and reporting [4, 5].

The purpose of the present study was to critically appraise the methodological rigour and transparency of CPGs issued by the leading organizations on the minimally-invasive treatment of BPO using the AGREE II instrument and to evaluate the comprehensiveness of surgical and minimally invasive BPH treatment methods as presented in the CPGs.

Materials and Methods

We included recent updates of full texts of clinical guidelines for surgical minimally invasive treatment of BPH. The guidelines by any other national associations or non-English guidelines were excluded. The largest English-speaking urological societies' guidelines were used. In this analysis, current guidelines from the European Association of Urology (EAU) [6], American Urological Association (AUA) [7] and National Institute for Health and Care Excellence (NICE) [8] were included. We used AGREE-II tool (version 2, December 2017 update) to assess the quality of these guidelines.

AGREE-II instrument consists of 23 items that are scored on a 7-point scale ranging from 1 (strongly disagree, which means that no relevant information is provided) to 7 (strongly agree, which means that the quality of reporting is excellent). These 23 items are grouped into 6 domains [5].

Final domain scores were calculated by summing up all the item scores within the domain and by scaling the total as a percentage of the maximum possible score for that domain [5].

Four urologists (optimal according to AGREE II) with differing levels of expertise (1- <5 years, 2-3- 5–10 years and 4- >15 years) were trained to use the AGREE II rating system (the training tools are available online at www.agreetrust.org). All the participants practice outside the jurisdictions of the guidelines (EU, USA, UK).

The participants independently appraised and scored each guideline. The scores were then expressed as standardized domain scores on a percent scale ranging from 0 to 100% (a percentage of the maximum possible score for each particular domain).

The performance in each domain was evaluated using a threshold of 60%. In addition, the total score (expressed as median and IQR) of the guidelines and the domains was calculated. Domain scores were categorized as good ($\geq 80\%$), acceptable (60–79%), low (40–59%), or very low ($<40\%$) [9, 10].

Results

Basic Features of Included Guidelines

European Association of Urology

The EAU guideline [6] latest version was published in 2020 and is updated annually. Members of the Panel incorporated into the guidelines for ease of evidence acquisition and synthesis strictly systematic reviews with meta-analysis, RCTs, and prospective non-randomized comparative studies. All collected data are assessed and graded according to the GRADE approach. Based on these forms, the team determined how strong the rating was and assigned each recommendation a “strong” or “weak” rating.

American Urological Association

The AUA guideline [7] latest version was published in 2019, an update of the previous one released in 2010. The evidence review team identified eligible RCTs, clinical controlled trials (CCTs), systematic reviews/meta-analyses, and observational studies. The team also used the Cochrane Collaboration's tool for assessing risk of bias. Overall quality of evidence was evaluated using the GRADEpro software. The quality of evidence (graded from A–C) and Linking statement type (strong, moderate and conditional recommendations, clinical principle and expert opinion) are assigned to each recommendation.

National Institute for Health and Care Excellence

The NICE [8] guideline was published in 2010, updated in 2015 and some additional files were released in 2019. The development group assessed the quality using the GRADE system and graded it according to NICE Guidelines Manual. The NICE development group does not assign strength rating or linking statement type, etc. They explain each recommendation by giving information about the values of different outcomes, clinical benefits and harms, economic considerations, quality of evidence (by discussing it) and some other considerations.

Table 1. AGREE results for each domain and overall assessment

	EAU, %	AUA, %	NICE, %
Scope and purpose	56.9 (Low)	66.7 (Acceptable)	94.4 (Good)
Stakeholder involvement	25.0 (Low)	50.0 (Low)	61.1 (Acceptable)
Rigor of development	62.5 (Acceptable)	65.1 (Acceptable)	83.9 (Good)
Clarity of presentation	91.7 (Good)	80.6 (Good)	79.2 (Acceptable)
Applicability	32.3 (Low)	33.3 (Low)	56.3 (Low)
Editorial independence	79.2 (Acceptable)	60.4 (Acceptable)	72.9 (Acceptable)
Overall assessment	79.1 (Acceptable)	83.3 (Good)	91.6 (Good)
I would recommend this guideline for use	All–Yes	All–Yes	All–Yes

AGREE-II Evaluation Results

Domain 1 Scope and Purpose

The AGREE-II quality scores for domain 1 ranged from 56.9 to 94.4% with a median score (IQR) of 66.7% (61.8–80.5%). AUA and NICE scores were >60% in the domain 1. However, the score of EAU was <60% with the lower scores in objectives description, health questions and study populations.

Domain 2 Stakeholder Involvement

The AGREE II quality scores for domain 2 ranged from 25.0 to 61.1% with a median score (IQR) of 50.0% (37.5–55.6%). The included CPGs reported minimal information about patient's preferences or target users of the guidelines and subsequently were assigned low scores.

Domain 3 Rigor of Development

The AGREE II quality scores for domain 3 ranged from 62.5 to 83.9% with a median score (IQR) of 65.1% (63.8–74.5%). All CPGs scores were >60% in the domain 3. However, the most common weaknesses across all CPGs were the following: the methods for formulating the recommendations and external review.

Domain 4 Clarity of Presentation

The AGREE II quality scores for domain 4 ranged from 79.2 to 91.7% with a median score (IQR) of 80.6% (79.9–86.2%). This domain was well-addressed in all the CPGs that were included. Recommendations were informative, specific, and key issues were easily identifiable. Moreover, the highest median score was in this domain (median 80.6%) with minimal variability.

Domain 5 Applicability

The AGREE II quality scores for domain 5 ranged from 32.3 to 56.3% with a median score (IQR) of 33.3% (32.8–44.8%). The NICE guideline received the highest

score. However, none of the CPGs received a score above 60% (EAU–32.3%; AUA–33.3%; NICE–56.3%). The information regarding barriers, facilitators, the monitoring and auditing of criteria was missing in most of the CPGs. This domain is characterized by the lowest median score of 33.3%, with a medium variability.

Domain 6 Editorial Independence

The AGREE II quality scores for domain 6 ranged from 60.4 to 79.2% with a median score (IQR) of 72.9% (66.6–76.1%). All the guidelines scored >60% and provided adequate information about competing interests. EAU guidelines include a conflict of interest disclosure for each panel member which states that no external sources of funding were involved. As for the AUA guidelines, there is also a conflict of interest disclosure which must be completed by each co-author. Where the NICE guidelines is concerned, a conflict of interest is listed not only for the panel members, but also for the studies which were assessed to develop the guidelines.

The difference between the appraisers' score within each domain was not >2 points (at 7-point scale). The median score (IQR) of overall assessment is 83.3% (79.1–91.6%). The highest score was received by NICE guidelines (91.6%) and the lowest–EAU guidelines (79.1%). Overall, the NICE guideline scored highest on 5 out of the 6 domains, the EAU guideline scored lowest on 4 out of the 6 domains with the AGREE II instrument (Table 1).

Surgical Treatment for BPH <80 cm³ (Table 2)

Transurethral Resection of the Prostate (TURP) and Transurethral Incision of the Prostate (TUIP)

All the included guidelines state bi- or monopolar TURP as the standard option for the treatment of men with BPH. Only the EAU guideline recommends this method for patients with prostate volume not >80 cm³. Beyond that, the associations recommend using transure-

Table 2. Surgery recommendations

Method	Association	Indication
TUIP	EAU 2020	Prostate volume <30 cm ³ Without a middle lobe
	AUA 2019	Prostate volume ≤30 cm ³
	NICE 2015	Prostate volume <30 cm ³ As an alternative to other types of surgery
TURP	EAU 2020	Prostate volume 30–80 cm ³ May use bipolar- or monopolar approach
	AUA 2019	As a treatment option for men with LUTS Monopolar or bipolar approach (depending on specialist's expertise with these techniques)
	NICE 2015	Monopolar or bipolar TURP
Simple prostatectomy	EAU 2020	Prostate volume >80 cm ³ In the absence of endoscopic enucleation
	AUA 2019	For patients with large prostates Consider open, laparoscopic or robotic assisted SP, depending on surgeon's expertise with these techniques
	NICE 2015	Prostate volume >80 cm ³ As an alternative to TURP, TUVF or HoLEP
Laser enucleation	EAU 2020	HoLEP As an alternative to TURP or OP
		120-W 980 nm diode laser or 1,318 nm diode laser As a comparable alternative to TURP or bipolar enucleation
		ThuVEP and ThuLEP As alternatives to TURP and holmium laser enucleation (HoLEP)
	AUA 2019	HoLEP or ThuLEP As prostate size-independent suitable options Choice depending on specialist's expertise with either technique
	NICE 2015	HoLEP
		For managing voiding LUTS Perform HoLEP at a center specializing in the technique, or with mentorship arrangements in place

thral incision of the prostate (TUIP) in case of small glands (<30 cm³).

Vaporization

The EAU, AUA and NICE guidelines agree on the use of the electro- or laser vaporization for BPO treatment. The EAU guidelines recommend laser vaporization primarily for patients with prostate volume 30–80 cm³ as an alternative to TURP. The same indications apply for bipolar transurethral vaporization (TUVF). The AUA guidelines do not mention any restrictions on vaporization by prostate size. The NICE working group reported

that bipolar TUVF, transurethral vaporessection of the prostate (TUVRP) and laser vaporization techniques may be used only as a part of clinical trials in comparison with TURP. The only technique with a clear recommendation is vaporization with GreenLight XPS laser in non-high-risk patients (with low bleeding risk, prostate size <100 cm³ and without urinary retention).

Surgical Treatment for BPH >80 cm³ (Table 2)

Simple Prostatectomy (SP)

In their guidelines, the Associations under consideration describe open SP as a treatment option for large pros-

Table 2 (continued)

Method	Association	Indication
Vaporization and its modifications	EAU 2020	80-W 532-nm KTP laser vaporization Prostate volume 30–80 cm ³ As an alternative to TURP
		120-W, 180-W 532-nm LBO laser vaporization Prostate volume 30–80 cm ³ As an alternative to TURP
		120-W 980 nm diode laser vaporization As a comparable alternative to TURP
		ThuVARP As an alternative to TURP
		Bipolar TUVF Prostate volume 30–80 cm ³ As an alternative to TURP
	AUA 2019	Bipolar TUVF Treatment of LUTS attributed to BPH
		PVP using 120W or 180W platforms Treatment of LUTS attributed to BPH
	NICE 2015	Monopolar TUVF For managing voiding LUTS
		Laser vaporization techniques, bipolar TUVF or monopolar or bipolar TUVRP As part of a RCT that compares these techniques with TURP
		GreenLight XPS in non-high-risk patients Is at least as effective in these patients as TURP As a day-case procedure, following appropriate service redesign
		GreenLight XPS in high-risk patients Insufficient high-quality, comparative evidence to support the routine adoption of GreenLight XPS in such group Hospitals may be redesigned for day-case treatment
Patients on antiplatelet or anticoagulant therapy	EAU 2020	ThuVEP ThuVARP
		Laser vaporization of the prostate using 80-W KTP, 120- or 180-W LBO lasers Prostate volume <80 cm ³
	AUA 2019	HoLEP PVP ThuLEP
	NICE 2015	N/A

HoLEP, Holmium laser enucleation of the prostate; KTP, Potassium-Titanyl-Phosphate; LBO, Lithium Borate; LUTS, Lower Urinary Tract Symptoms; OP, Open prostatectomy; PVP, Photoselective Vaporization of the Prostate; TUIP, Transurethral incision of the prostate; TURP, Transurethral resection of the prostate; TUVF, Transurethral Vaporization of Prostate; TUVRP, transurethral vaporessection of the prostate; ThuLEP, Thulium laser enucleation of the prostate; ThuVARP, Tm; YAG, laser vaporessection; ThuVEP, Thulium VapoEnucleation of the prostate; AUA, American Urological Association; EAU, European Association of Urology; NICE, National Institute for Health and Care Excellence.

Table 3. Minimally invasive treatment indications with some comment from guidelines

Method	Association	Indication/comments
Prostatic urethral lift	EAU 2020	Prostate volume <70 cm ³ Absence of middle lobe Interested in preserving ejaculatory function
	AUA 2019	Prostate volume <80 cm ³ Verified absence of an obstructive middle lobe To eligible patients concerned with erectile and ejaculatory function Patients should be informed of its inferiority to TURP
	NICE 2015	Prostate volume <100 cm ³ Patients age >50 years Without an obstructing middle lobe As an alternative to current surgical procedures for use in a day-case setting
Aquablation	EAU 2020	Prostate volume 30–80 cm ³ As an alternative to TURP Inform patients of the risk of bleeding and the lack of long-term follow up data
	AUA 2019	Prostate volume 30–80 cm ³ Patients should be informed that long term evidence of efficacy and retreatment rates remains limited
	NICE 2015	The evidence on efficacy is limited in quantity The procedure should only be used with special arrangements for clinical governance, consent, and audit or research The procedure should only be done by clinicians who have been trained in the technique
Prostatic artery embolization	EAU 2020	For patients who wish to consider minimally invasive treatment options and accept less optimal objective outcomes compared with TURP Only in units where the work up and follow up is performed by urologists working collaboratively with trained interventional radiologists
	AUA 2019	Use PAE for LUTS treatment only in the context of a clinical trial
	NICE 2015	This procedure can only be applied provided that standard arrangements are in place for clinical governance, consent and audit Patient selection should be done by a urologist and an interventional radiologist Procedure should only be done by an interventional radiologist with specific training and expertise in PAE
Mini invasive simple prostatectomy	EAU 2020	Prostate volume >80 cm ³ However, RCTs are needed
	AUA 2019	NA
	NICE 2015	NA
Intra-prostatic injections	EAU 2020	Do not offer intraprostatic Botulinum toxin-A injection treatment to patients with male LUTS
	AUA 2019	NA
	NICE 2015	Consider offering botulinum toxin injection into the prostate only as part of a RCT

tates with minor differences. The EAU mentioned open SP when EEP was not available. The AUA suggests considering open, laparoscopic or robotic assisted SP, depending on the surgeon expertise. The NICE guideline stated open SP as an alternative to TURP, TUVF or HoLEP.

Enucleation

The EAU and AUA working groups offer enucleation for patients with prostate size >80 cm³. EAU stated that Holmium laser enucleation (HoLEP) is the current standard for large prostates and is an alternative to TURP or

Table 3 (continued)

Method	Association	Indication/comments
Water vapor thermal therapy	EAU 2020	NA
	AUA 2019	Prostate volume <80 cm ³ However, patients should be counseled regarding efficacy and retreatment rates May be offered to eligible patients who desire preservation of erectile and ejaculatory function
	NICE 2015	This procedure can only be applied provided that standard arrangements are in place for clinical governance, consent and audit Procedure should only be done by a urologist with specific training in the procedure, who should carry out their initial procedures with an experienced mentor
Prostatic urethral temporary implant insertion	EAU 2020	NA
	AUA 2019	NA
	NICE 2015	Evidence on the safety and efficacy is limited in quantity and quality The procedure should only be used in the context of research Further research is needed
Minimally invasive treatments (TUMT, TUNA, HIFU, TEAP)	EAU 2020	NA
	AUA 2019	TUNA is not recommended for the treatment of LUTS attributed to BPH TUMT may be offered However, patients should be informed that surgical retreatment rates are higher compared to TURP
	NICE 2015	Do not offer minimally invasive treatments (including TUNA, TUMT, HIFU, TEAP and laser coagulation) as an alternative to TURP, TUVF or HoLEP

HIFU, High-intensity focused ultrasound; HoLEP, Holmium laser enucleation of the prostate; LUTS, Lower Urinary Tract Symptoms; PAE, Prostatic artery embolization; RCT, Randomized clinical trial; TEAP, Transurethral ethanol ablation of the prostate; TUMT, Transurethral microwave thermotherapy; TUNA, Transurethral needle ablation; TURP, Transurethral resection of the prostate; TUVF, Transurethral Vaporization of Prostate; AUA, American Urological Association; EAU, European Association of Urology; NICE, National Institute for Health and Care Excellence.

open SP. According to European recommendations, specialists can also use diode or thulium laser for enucleation, the latter being an alternative to HoLEP. The AUA recommends HoLEP and thulium laser enucleation (ThuLEP) as prostate size-independent procedures. The NICE guidelines are not very specific when it comes to recommendations regarding laser enucleation methods.

Surgical Treatment for Patients on Antithrombotic Agents (Table 2)

The EAU and AUA recommend laser treatment (enucleation or vaporization) for patients on anticoagulant/antiplatelet therapy. Similarly, the EAU recommends laser modalities: HoLEP, vapoenucleation and vaporessection with Tm:YAG laser and vaporization with 532-nm Potassium-Titanyl-Phosphate (KTP) or 532-nm Lithium

Borat (LBO) lasers. The NICE team discusses the implementation of GreenLight XPS as a possible option but notices that there is insufficient high-quality evidence.

Minimally Invasive Interventions (Table 3)

Prostatic Urethral Lift (PUL)

All associations offer PUL with some variations in indications, a permitted prostate size being one of them. The EAU recommends <70 cm³, the AUA– <80 cm³ and the NICE– <100 cm³. The AUA also points to the need for informing the patients about PUL's inferiority to TURP. Where the NICE guideline is concerned, PUL is thought to be suitable for men older than 50.

Aquablation/Waterjet Ablation

The EAU and AUA offer waterjet ablation (aquablation) as a treatment option for men with prostate volume

30–80 cm³, but both guidelines highlight the lack of long-term follow up data. The NICE guideline recommends water jet ablation as 1 possible option. The association states that the evidence on efficacy is limited, that the procedure should only be done within clinical trials settings.

Prostatic Artery Embolization (PAE)

The EAU guideline recommends PAE for patients who want to consider minimally invasive treatment options despite less optimal objective outcomes compared with TURP. The AUA considers PAE only for clinical trials. The NICE indications are similar to the EAU.

Intra-Prostatic Injections

Both the EAU and NICE make mention of intra-prostatic injections. Whereas the EAU discarded intraprostatic Botulinum toxin-A injection, the NICE guideline offers it only as a part of a RCT. The AUA does not discuss it.

Water Vapor Thermal Therapy

The AUA team states that it is a suitable option for patients with a prostate volume <80 cm³, and for those who have already been informed about its safety and efficacy and want to preserve their sexual function. The NICE guideline points out that the procedure should only be done by specifically trained urologists. The EAU states that randomized controlled trials against a reference technique are needed to confirm the first results.

Prostatic Urethral Temporary Implant Placement

The NICE working group proposes using a prostatic urethral temporary implant only within clinical trials because the evidence on the safety and efficacy is limited in terms of its quantity and quality. The EAU and AUA do not discuss this procedure.

Other Minimally Invasive Treatments

Besides the abovementioned methods, the AUA recommends using transurethral microwave thermotherapy (TUMT) only for patients who have been informed that surgical retreatment rates are higher compared to TURP. It also does not recommend transurethral needle ablation (TUNA). The NICE guideline does not offer TUMT, TUNA, high-intensity focused ultrasound (HIFU), transurethral ethanol ablation of the prostate (TEAP) as an alternative to TURP, TUVF or HoLEP. The EAU makes no mention of them.

Discussion

To our knowledge, this study is the first to evaluate the development and reporting quality of CPG, as proposed by the AGREE-II tool [5]. Our review focused on the most recent updates of the international association guidelines [6–8]. The overall scores for the guidelines showed that all 3 guidelines are being rigorously developed and serve as examples of well-designed CPGs. The NICE scored best with 91.6%, whereas the EAU and AUA scored 79.1 and 83.3%, respectively.

The guidelines aim to improve the quality of patient care and reduce unnecessary differences in practice [11]. The main target audience for the guidelines are urologists, therefore in our study we purposefully included practicing urologists without any other specific qualification (e.g., in field of linguistics or data analysis) to appraise the guidelines. Amongst the 6 parameters assessed with AGREE II, the overall domain scores for clarity of presentation were the highest (80.6%) with minor variance between the 3 guidelines. This domain represents how the CPGs are dealing with the main goal—reporting effective treatment options for different patients. We believe that despite lower scores in other domains, a high score in this field signifies the clinical importance of all the guidelines (EAU–91.7%; AUA–80.6%; NICE–79.2%). The domains relating to editorial independence, scope and purpose yielded the second and third best scores respectively.

One of the least scored domains was “Applicability” with a score of 33.3% (EAU–32.3%; AUA–33.3%; NICE–56.3%). The latter is the anticipated finding as most of the guideline development groups did not indicate the barriers or facilitators to implementing guideline recommendations and did not provide ways to audit effective implementation. Being a secondary goal in guideline development, the applicability is an important point that should be considered by the Panels. However, the applicability of the guidelines is not limited to methods of implementation and as suggested by Speakman et al. [12] should include a discussion of how Panels evaluate new methods. The authors believe that this may result in minimizing the misuse under commercial pressure, particularly in private healthcare centers [12].

The domain stakeholder involvement was also ranked low with a score of 50.0% (EAU–25.0%; AUA–50.0%; NICE–61.1%). After the evaluation process, we found that most guidelines did not highlight the views and preferences of the target population and did not clearly define the target users. The NICE guidelines reported the broad-

est spectrum of Panel participants and were more precise in defining target users. The absence of precise data on stakeholder involvement should not be considered a major limitation to the guidelines, but it could significantly improve the applicability of the guidelines for patients.

The stakeholder involvement and applicability domains were also ranked lowest in the study of Xu et al. [13], who compared guidelines on α 1-blockers and 5 α -reductase inhibitors administration. The lack of target population views and implementation mechanisms were described by Gupta et al. [14] in assessing the prostate cancer guidelines (stakeholder involvement and applicability were also ranking lowest). Discussing guidelines on smoking cessation, Sharma et al. [15] assign 54.2 and 33.3% respectively for the rigour of development and editorial independence domains. Such consistency in CPGs design may signify another important limitation to modern medical practice—we are more prone to focus on the estimated efficacy and percent of complications rather than report the actual needs of the population.

The differences in surgical options among the included guidelines were insignificant. First, each association recommends a different range of methods. Such discrepancies could emerge because the working groups had used different search strategy and included different studies for evidence synthesis. The EAU selected strictly systematic reviews, RCTs and prospective non-randomized comparative studies. The AUA, in addition to the abovementioned, also included observational and clinical controlled trials. The NICE guidelines did not limit search strategy and used free-text terms. This differences in approaches have been previously mentioned by Speakman et al. [12] where they discussed how the EAU panel evaluates papers. Such a rigorous approach to selecting and assessing articles allowed EAU scored first in the domain of clarity of presentation. The second possible reason for the differences is the updating process. The EAU CPG are only being updated annually.

The EAU CPG 2021 have been released recently. No changes in methodology or editorial board comparing with the previous year guidelines took place, thus the newest guidelines obviously have the same score for domains 1–3 and 6. The main change in terms of surgical treatment was restructuration of the section: while previous year it was divided according to specific technologies, now they are grouped depending on the surgical technique as follows: resection, enucleation, vaporization, alternative ablative techniques. The same urologists ranked this new edition of EAU guidelines for domain 4 and 5 and got the same results as for the previous version.

The AGREE tool was elaborated in 2003 as an instrument for CPG evaluation [4] and has been amended recently [5, 16, 17]. Unfortunately, high AGREE II scores do not guarantee high quality of CPGs. Despite the presence of high and rather low ranked domains, the included guidelines are of high-quality and clearly reflected all the relevant information about BPH treatment. Notwithstanding, using many appraisal tools, AGREE II was shown to be a reliable assessment instrument with the highest potential [18].

This study has several limitations. Firstly, CPGs were appraised only by urologists. However, it should be borne in mind that it was a large team comprising both less- and highly experienced specialists. Secondly, the AGREE II tool is not an ideal instrument, but it remains one of the most reliable. The inability to distinguish significant differences between 2 similar scores is one of the major limitations of the AGREE II, and the only reliable threshold suggested is 60% distinguishing between low and acceptable levels.

Conclusions

The analyzed CPGs comprehensively highlight the minimally invasive and surgical treatment options for BPH. According to the AGREE II tool, the domains for clarity of presentation and editorial independence received the highest scores. The stakeholder involvement and applicability domains were ranked as the lowest. Improving the CPG in these domains may help to improve the clinical utility and applicability of CPGs.

Statement of Ethics

The paper is exempt from ethical committee approval because this study is a literature review and did not involve humans or animals.

Conflict of Interest Statement

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Funding Sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contributions

D. Enikeev: Data analysis, Protocol development. V. Misrai: Manuscript editing. E. Rijo: Manuscript editing. R. Sukhanov: Data collection, Manuscript editing. D. Chinenov: Data collection, Manuscript editing. M. Gazimiev: Data collection, Manuscript editing. M. Taratkin: Data analysis, Manuscript writing. C. Azilgareva: Data analysis, Manuscript writing. A. Morozov: Data analysis, Manuscript editing. T.R.W. Herrmann: Manuscript editing. P. Glybochko: Protocol development, Manuscript editing.

Data Availability Statement

Data are available on demand.

References

- 1 Takamori H, Masumori N, Kamoto T. Surgical procedures for benign prostatic hyperplasia: a nationwide survey in Japan, 2014 update. *Int J Urol*. 2017;24(6):476–7.
- 2 Morton A, Williams M, Perera M, Teloken PE, Donato P, Ranasinghe S, et al. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. *BJU Int*. 2020;126(Suppl 1):18–26.
- 3 Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). *Urology*. 2012;79(5):1111–6.
- 4 Cluzeau F, Burgers J, Brouwers M, Grol R, Mäkelä M, Littlejohns P, et al. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care*. 2003;12(1):18–23.
- 5 Koufogiannakis D, Brett A. Agree. In *Being evidence based in library and information practice*. Facet; 2018. p. 59–70.
- 6 Gravas S, Cornu JN, Gacci M, Gratzke C. *EAU Guidelines. Management of non-neurogenic male LUTS*. 2019 Jun. p. 10–2.
- 7 Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. *J Urol*. 2019;202(3):592–8.
- 8 National Institute for Health and Care Excellence. [The management of lower urinary tract symptoms in men produced by the National Clinical Guideline Centre](#). 2010. p. 353.
- 9 Doniselli FM, Zanardo M, Manfrè L, Papini GDE, Rovira A, Sardanelli F, et al. A critical appraisal of the quality of low back pain practice guidelines using the AGREE II tool and comparison with previous evaluations: a EuroAIM initiative. *Eur Spine J*. 2018;27(11):2781–90.
- 10 Sekercioglu N, Al-Khalifah R, Ewusie JE, Elias RM, Thabane L, Busse JW, et al. A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument. *Int Urol Nephrol*. 2017;49(2):273–84.
- 11 Chen Q, Lu W, Kupelian P, Langen K, Meeks S, Ruchala K, et al. SU-FF-J-85: automatic seed detection in MVCT images for prostate radiotherapy. *Med Phys*. 2005;32(6):1939.
- 12 Speakman MJ, Cornu JN, Gacci M, Gratzke C, Mamoulakis C, Herrmann TRW, et al. What is the required certainty of evidence for the implementation of novel techniques for the treatment of benign prostatic obstruction? *Eur Urol Focus*. 2019;5(3):351–6.
- 13 Xu X-F, Liu G-X, Zhu C, Qiao X-M, Yu S-F, Deng T, et al. α 1-Blockers and 5 α -reductase inhibitors are the most recommended drugs in treating benign prostatic hyperplasia: an evidence-based evaluation of clinical practice guidelines. *Front Pharmacol*. 2020;11:311.
- 14 Gupta M, McCauley J, Farkas A, Gudeloglu A, Neuberger MM, Ho YY, et al. Clinical practice guidelines on prostate cancer: a critical appraisal. *J Urol*. 2015;193(4):1153–8.
- 15 Sharma R, Alla K, Pfeffer D, Meurk C, Ford P, Kisely S, et al. An appraisal of practice guidelines for smoking cessation in people with severe mental illness. *Aust N Z J Psychiatry*. 2017;51(11):1106–20.
- 16 Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. *CMAJ*. 2010;182(10):1045–52.
- 17 Brouwers MC, Spithoff K, Kerkvliet K, Alonso-Coello P, Burgers J, Cluzeau F, et al. Development and validation of a tool to assess the quality of clinical practice guideline recommendations. *JAMA Netw Open*. 2020;3(5):e205535.
- 18 Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D. A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. *Int J Qual Health Care*. 2005;17(3):235–42.